EX-23.1 4 apls-ex23_1.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statement Nos. 333-269899, 333-

235830 and 333-229091 on Form S-3 and Registration Statement Nos. 333-229876, 333-221528,

333-236708, 333-236710, 333-253518, 333-263100 and 333-269888 on Form S-8 of our reports

dated February 27, 2024, relating to the financial statements of Apellis Pharmaceuticals, Inc. and its

subsidiaries and the effectiveness of Apellis Pharmaceuticals, Inc. and its subsidiaries’ internal control

over financial reporting appearing in this Annual Report on Form 10-K for the year ended December

31, 2023.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

February 27, 2024